These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 35220644)

  • 1. Coverage with evidence development for medical devices in Europe: Can practice meet theory?
    Drummond M; Federici C; Reckers-Droog V; Torbica A; Blankart CR; Ciani O; Kaló Z; Kovács S; Brouwer W
    Health Econ; 2022 Sep; 31 Suppl 1(Suppl 1):179-194. PubMed ID: 35220644
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Coverage with evidence development schemes for medical devices in Europe: characteristics and challenges.
    Federici C; Reckers-Droog V; Ciani O; Dams F; Grigore B; Kaló Z; Kovács S; Shatrov K; Brouwer W; Drummond M
    Eur J Health Econ; 2021 Nov; 22(8):1253-1273. PubMed ID: 34117987
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Implementation of coverage with evidence development schemes for medical devices: A decision tool for late technology adopter countries.
    Kovács S; Kaló Z; Daubner-Bendes R; Kolasa K; Hren R; Tesar T; Reckers-Droog V; Brouwer W; Federici C; Drummond M; Zemplényi AT
    Health Econ; 2022 Sep; 31 Suppl 1(Suppl 1):195-206. PubMed ID: 35322478
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Uncertainty and Coverage With Evidence Development: Does Practice Meet Theory?
    Pouwels XGLV; Grutters JPC; Bindels J; Ramaekers BLT; Joore MA
    Value Health; 2019 Jul; 22(7):799-807. PubMed ID: 31277827
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force.
    Garrison LP; Towse A; Briggs A; de Pouvourville G; Grueger J; Mohr PE; Severens JL; Siviero P; Sleeper M
    Value Health; 2013; 16(5):703-19. PubMed ID: 23947963
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Coverage with evidence development: the Ontario experience.
    Levin L; Goeree R; Levine M; Krahn M; Easty T; Brown A; Henry D
    Int J Technol Assess Health Care; 2011 Apr; 27(2):159-68. PubMed ID: 21473814
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Coverage with Evidence Development: applications and issues.
    Trueman P; Grainger DL; Downs KE
    Int J Technol Assess Health Care; 2010 Jan; 26(1):79-85. PubMed ID: 20059784
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Alternative access schemes for pharmaceuticals in Europe: Towards an emerging typology.
    Löblová O; Csanádi M; Ozierański P; Kaló Z; King L; McKee M
    Health Policy; 2019 Jul; 123(7):630-634. PubMed ID: 31130319
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Special funding schemes for innovative medical devices in French hospitals: the pros and cons of two different approaches.
    Martelli N; van den Brink H
    Health Policy; 2014 Jul; 117(1):1-5. PubMed ID: 24794738
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Quo Vadis HTA for Medical Devices in Central and Eastern Europe? Recommendations to Address Methodological Challenges.
    Daubner-Bendes R; Kovács S; Niewada M; Huic M; Drummond M; Ciani O; Blankart CR; Mandrik O; Torbica A; Yfantopoulos J; Petrova G; Holownia-Voloskova M; Taylor RS; Al M; Piniazhko O; Lorenzovici L; Tarricone R; Zemplényi A; Kaló Z
    Front Public Health; 2020; 8():612410. PubMed ID: 33490024
    [No Abstract]   [Full Text] [Related]  

  • 11. The future of Cochrane Neonatal.
    Soll RF; Ovelman C; McGuire W
    Early Hum Dev; 2020 Nov; 150():105191. PubMed ID: 33036834
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Market Access Agreements for pharmaceuticals in Europe: diversity of approaches and underlying concepts.
    Jarosławski S; Toumi M
    BMC Health Serv Res; 2011 Oct; 11():259. PubMed ID: 21982545
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pricing of pharmaceuticals. Assessing the pricing potential by a pricing matrix model.
    Nuijten MJ; Kosa J
    Eur J Health Econ; 2004 Jun; 5(2):110-5. PubMed ID: 15452745
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework.
    Murphy P; Glynn D; Dias S; Hodgson R; Claxton L; Beresford L; Cooper K; Tappenden P; Ennis K; Grosso A; Wright K; Cantrell A; Stevenson M; Palmer S
    Health Technol Assess; 2021 Dec; 25(76):1-228. PubMed ID: 34990339
    [TBL] [Abstract][Full Text] [Related]  

  • 15. From market access to patient access: overview of evidence-based approaches for the reimbursement and pricing of pharmaceuticals in 36 European countries.
    Panteli D; Eckhardt H; Nolting A; Busse R; Kulig M
    Health Res Policy Syst; 2015 Sep; 13():39. PubMed ID: 26407728
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The HTA Risk Analysis Chart: Visualising the Need for and Potential Value of Managed Entry Agreements in Health Technology Assessment.
    Grimm SE; Strong M; Brennan A; Wailoo AJ
    Pharmacoeconomics; 2017 Dec; 35(12):1287-1296. PubMed ID: 28849538
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishing the cost-effectiveness of new pharmaceuticals under conditions of uncertainty--when is there sufficient evidence?
    Sculpher M; Claxton K
    Value Health; 2005; 8(4):433-46. PubMed ID: 16091019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Health technology assessment of medical devices: What is different? An overview of three European projects.
    Schnell-Inderst P; Mayer J; Lauterberg J; Hunger T; Arvandi M; Conrads-Frank A; Nachtnebel A; Wild C; Siebert U
    Z Evid Fortbild Qual Gesundhwes; 2015; 109(4-5):309-18. PubMed ID: 26354131
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A MEA is a MEA is a MEA? Sequential decision making and the impact of different managed entry agreements at the manufacturer and payer level, using a case study for an oncology drug in England.
    Buyukkaramikli NC; Wigfield P; Hoang MT
    Eur J Health Econ; 2021 Feb; 22(1):51-73. PubMed ID: 32901420
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world evidence in health technology assessment of high-risk medical devices: Fit for purpose?
    Klein P; Blommestein H; Al M; Pongiglione B; Torbica A; Groot S
    Health Econ; 2022 Sep; 31 Suppl 1(Suppl 1):10-24. PubMed ID: 35989520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.